MEDICAL PRODUCTS
Human Ultracell V IM
Human Ultracell V Oral
Human Citoplacell 3G
Revercell 3G
Cellorgane Multi-Complex 3G
Androcell 3G
Biofemin 3G
Bioenzym 3G
Celltox 3G
Mekenz H7 3G
Cellorgane Man
Cellorgane Woman
Formula 1 Skin & Muscle
Formula 2 Liver
Formula 3 Heart-Artery-Vein
Formula 4 Bone-Cartilage
Formula 5 Kidney - Nephrons
Formula 6 Lungs
Formula 7 Brain-Hypothalamus-Pituitary
Formula 8 Adrenal Gland
Formula 9 Thymus - Spleen
Formula 10 Pancreas
Formula 11 Esophagus-Stomach-Intestines
Formula 12 Thyroid
LOGGED IN
No one logged in.

Protocols: Menopause, Climacteric, and Lack of Libido

Gynecology and General Medicine

Menopause is defined as the permanent cessation of menstruation. It has physiological correlations, with a decline in the secretion of estrogens due to the loss of follicle function. It is one step within the slow and long process of reproductive aging. This term is often confused with climacteric, which is actually a term that can be applied to both genders.  

The average age of menopause, when a women has her last period, is 51.4 years.  This last period is preceded by climacteric, which is the transition phase between the reproductive and non-reproductive stages of a woman’s life.  This process begins several years before the last period, when the cycle (or menstrual period) starts to become less regular. 

Decrease in the levels of the hormones estrogen and progesterone causes changes in menstruation. These hormones are important to maintain the vagina and uterus in good health, for normal menstrual cycles and for a successful pregnancy. Estrogen also keeps bones healthy and helps women maintain blood cholesterol at healthy levels.

The gradual decrease in female hormone levels until their total disappearance causes the appearance of a series of related signs and symptoms, as well as an increase in rage for some women.

The appearance of each of them, as well as their seriousness and importance with respect to a decrease in quality of life, depends on each individual woman. In any case, there are a great number of therapeutic options now that can help mitigate the symptoms or ailments associated with menopause.

Therapies based on phytoestrogens are among the most common as alternatives to Hormone Replacement Therapy. Phytoestrogens are non-steroid, plant-based compounds of varied structure that are found in many fruits, vegetables, and grains. (Knight 1996; Thompson 1991). The most common types of phytoestrogens are coumestans, lignans, and isoflavones.

These compounds are structurally similar to estradiol (E2) and have been proven to have estrogenic activity (Makela 1994; Setchell 1998). When they are ingested they have been proven to have biological effects in human beings (Wilcox 1990). In humans, they seem to have estrogenic as well as antiestrogenic effects, depending on the concentrations of endogenic estrogens and estrogen receptors in the bloodstream (Cassidy 1993; Cassidy 1994).

From an estrogenic point of view, isoflavones are the most potent. The most important dietary isoflavones, genistein and diadzein, are found almost exclusively in legumes such as soy, chickpeas, lentils, and beans (Cassidy 1993). 

The urinary excretion of the weak estrogen equol in humans who consume diets with soy supplements may significantly excede the concentration of endogenous urinary estrogens and thus the plausibility of the physiological effects on human health is improved. Other classes of phytoestrogens, lignans, and prenylated flavonoids also have a potent estrogenic effect but they have not been studied as closely (Adlercreutz 1987; Milligan 1999).

Protocol 1 (Mild Menopause)

 

Administer 2 ml daily by deep intramuscular injection for 5 days, rest 2 days and adminis-ter another complete treatment course of 2 ml daily for 5 days (two boxes). Acts as Multi-Organ support. Treatment should be repeated after 6 months.

 

To be taken concurrently with the previous treatment, one capsule in the morning, one capsule at night before meals, continuously for six months, and then re-evaluate.

Protocol 2 (Moderate and Severe Menopause)

 

Administer 2 ml daily by deep intramuscular injection for 5 days, rest 2 days and adminis-ter another complete treatment course of 2 ml daily for 5 days (two boxes). Acts as Multi-Organ support. Treatment should be repeated after 6 months.

 

Cellorgane Multi-complex tablets, take 2 tablets in the morning (on an empty stomach) and 2 tablets at night (on an empty stomach), concurrently with injections of Cellorgane Multi-complex. Subsequently, it should be taken continuously for at least 3 months, and then re-evaluate.

Protocol 3 (Moderate Menopause + Depression)

 

To be administrated concurrently with the previous treatment, one capsule at morning and one at night, before meals, continuously for six months and then re-evaluate.

 

Apply 2 ml daily (deep intramuscular), during 5 days, rest for 2 days and reapply another complete treatment of 2ml daily during 5 days (2 boxes). It acts as Multi-organ support. The treatment must be reapplied at the next 6 months.

 

Administer concurrently with the previous treatment. Take one capsule in the morning and one at night, before meals, during 6 months and re-evaluate.

 

The Cellorgane Multi-complex treatment should be simultaneously reinforced with Cellor-gane Multi-complex No. 7, Take 2 tablets in the morning (on an empty stomach) and 2 Tablets at night (on an empty stomach). Treatment should be taken continuously for at least 3 months, and then re-evaluate. (Recommended to be taken together with Biofemin capsules.)

Who We Are

Biocell Ultravital™ researches and develops innovative, 100% natural, pharmaceutical-grade bioproducts, on an exclusive basis worldwide. These products optimise cell nutrition and energy, producing a preventative and curative action which, in addition to treating pre-symptoms and symptoms by means of cell renewal, refuels and corrects the cell structure of tissues and organs, preventing the appearance of the functional stress loads which give rise to poor cell formation, degenerative diseases, and their after-effects.

Policies

Product developed under pharmaceutical control according to European CE standards. Made in the EC by Biocell Laboratory France, licensed and authorized by Biocell Ultravital GmbH, Switzerland.

Privacy

This website is governed by applicable laws and government regulations. Please see our Privacy Policy.
Use of this site constitutes your consent to application of such laws and regulations.

© 2020 Biocell Ultravital